Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cellectis S.A. ADR (CLLS)

Cellectis S.A. ADR (CLLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 563,736
  • Shares Outstanding, K 42,450
  • Annual Sales, $ 21,430 K
  • Annual Income, $ -78,690 K
  • 60-Month Beta 1.77
  • Price/Sales 26.88
  • Price/Cash Flow N/A
  • Price/Book 1.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.80
  • Number of Estimates 2
  • High Estimate -0.63
  • Low Estimate -0.97
  • Prior Year -0.53
  • Growth Rate Est. (year over year) -50.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.61 +36.94%
on 10/14/19
13.63 -3.45%
on 11/11/19
+3.32 (+33.74%)
since 10/11/19
3-Month
9.50 +38.53%
on 10/10/19
13.63 -3.45%
on 11/11/19
-0.05 (-0.38%)
since 08/13/19
52-Week
9.50 +38.53%
on 10/10/19
25.86 -49.11%
on 11/14/18
-12.58 (-48.87%)
since 11/13/18

Most Recent Stories

More News
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019

Regulatory News:

CMVLF : 12.6000 (+6.96%)
CLLS : 13.19 (-0.68%)
Cellectis to Hold Third Quarter and First Nine Months 2019 Earnings Call on Thursday, November 7, 2019 at 8:00 AM EST

Regulatory News:

CMVLF : 12.6000 (+6.96%)
CLLS : 13.19 (-0.68%)
First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma

Regulatory News:

CMVLF : 12.6000 (+6.96%)
CLLS : 13.19 (-0.68%)
Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis' Allogeneic UCART Product Candidates

Regulatory News:

CMVLF : 12.6000 (+6.96%)
CLLS : 13.19 (-0.68%)
Cellectis Reports Financial Results for Second Quarter and First Six Months 2019

Regulatory News:

CMVLF : 12.6000 (+6.96%)
CLLS : 13.19 (-0.68%)
Cellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way

Regulatory News:

CMVLF : 12.6000 (+6.96%)
CLLS : 13.19 (-0.68%)
Cellectis S.A. Reports Results from Combined Shareholders Meeting Held on June 25, 2019

Regulatory News:

CMVLF : 12.6000 (+6.96%)
CLLS : 13.19 (-0.68%)
Cellectis Reports Financial Results for First Quarter 2019

--- FDA approved IND for UCARTCS1A product candidate in Multiple Myeloma

CMVLF : 12.6000 (+6.96%)
CLLS : 13.19 (-0.68%)
Cellectis Announces Oral and Poster Presentations of Allogeneic CAR T-Cell Programs at the 2019 ASGCT Annual Meeting

--- Poster presentation to focus on improved manufacturing for allogeneic CAR T-cells

CMVLF : 12.6000 (+6.96%)
CLLS : 13.19 (-0.68%)
Research Report Identifies Stamps, Chicken Soup for the Soul Entertainment, Marlin Business Services, OncoCyte, FBL Financial Group, and Cellectis S.A with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Stamps.com Inc. (NASDAQ:STMP),...

CMVLF : 12.6000 (+6.96%)
STMP : 85.37 (-2.60%)
CSSE : 9.61 (-1.03%)
MRLN : 21.21 (+0.14%)
OCX : 1.73 (+1.76%)
FFG : 58.90 (-0.34%)
CLLS : 13.19 (-0.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade CLLS with:

Business Summary

Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France.

See More

Key Turning Points

2nd Resistance Point 13.76
1st Resistance Point 13.52
Last Price 13.19
1st Support Level 13.08
2nd Support Level 12.88

See More

52-Week High 25.86
Fibonacci 61.8% 19.61
Fibonacci 50% 17.68
Fibonacci 38.2% 15.75
Last Price 13.19
52-Week Low 9.50

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar